Generic Drugs Gain Status Boost Within CDER
This article was originally published in The Pink Sheet Daily
More than just a bureaucratic shell game, the promotion of the Office of Generic Drugs to “super office” status signals CDER Director Janet Woodcock’s tightened focus on generic drugs.
You may also be interested in...
Sally Choe, who has been working in the Office of Translational Sciences, will take over for Kathleen Uhl in March.
US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.
January launch of long-awaited Office of Pharmaceutical Quality is part of broader Center reorganization that also includes new Office of Study Integrity and Surveillance.